Literature DB >> 20816875

The binding sites for benztropines and dopamine in the dopamine transporter overlap.

Heidi Bisgaard1, M Andreas B Larsen, Sonia Mazier, Thijs Beuming, Amy Hauck Newman, Harel Weinstein, Lei Shi, Claus J Loland, Ulrik Gether.   

Abstract

Analogs of benztropines (BZTs) are potent inhibitors of the dopamine transporter (DAT) but are less effective than cocaine as behavioral stimulants. As a result, there have been efforts to evaluate these compounds as leads for potential medication for cocaine addiction. Here we use computational modeling together with site-directed mutagenesis to characterize the binding site for BZTs in DAT. Docking into molecular models based on the structure of the bacterial homolog LeuT supported a BZT binding site that overlaps with the substrate-binding pocket. In agreement, mutations of residues within the pocket, including(2) Val152(3.46) to Ala or Ile, Ser422(8.60) to Ala and Asn157(3.51) to Cys or Ala, resulted in decreased affinity for BZT and the analog JHW007, as assessed in [(3)H]dopamine uptake inhibition assays and/or [(3)H]CFT competition binding assay. A putative polar interaction of one of the phenyl ring fluorine substituents in JHW007 with Asn157(3.51) was used as a criterion for determining likely binding poses and establish a structural context for the mutagenesis findings. The analysis positioned the other fluorine-substituted phenyl ring of JHW007 in close proximity to Ala479(10.51)/Ala480(10.52) in transmembrane segment (TM) 10. The lack of such an interaction for BZT led to a more tilted orientation, as compared to JHW007, bringing one of the phenyl rings even closer to Ala479(10.51)/Ala480(10.52). Mutation of Ala479(10.51) and Ala480(10.52) to valines supported these predictions with a larger decrease in the affinity for BZT than for JHW007. Summarized, our data suggest that BZTs display a classical competitive binding mode with binding sites overlapping those of cocaine and dopamine.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816875      PMCID: PMC3703859          DOI: 10.1016/j.neuropharm.2010.08.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  46 in total

1.  Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter.

Authors:  Rong Chen; Michael R Tilley; Hua Wei; Fuwen Zhou; Fu-Ming Zhou; San Ching; Ning Quan; Robert L Stephens; Erik R Hill; Timothy Nottoli; Dawn D Han; Howard H Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 2.  Neurotransmitter transporters: molecular function of important drug targets.

Authors:  Ulrik Gether; Peter H Andersen; Orla M Larsson; Arne Schousboe
Journal:  Trends Pharmacol Sci       Date:  2006-06-09       Impact factor: 14.819

3.  Novel procedure for modeling ligand/receptor induced fit effects.

Authors:  Woody Sherman; Tyler Day; Matthew P Jacobson; Richard A Friesner; Ramy Farid
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

Review 4.  Glutamate and monoamine transporters: new visions of form and function.

Authors:  Gonzalo E Torres; Susan G Amara
Journal:  Curr Opin Neurobiol       Date:  2007-05-16       Impact factor: 6.627

5.  A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function.

Authors:  Thijs Beuming; Lei Shi; Jonathan A Javitch; Harel Weinstein
Journal:  Mol Pharmacol       Date:  2006-07-31       Impact factor: 4.436

6.  Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling.

Authors:  Sangeeta Raje; Jennifer Cornish; Amy H Newman; Jianjing Cao; Jonathan L Katz; Natalie D Eddington
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

7.  Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors.

Authors:  Claus J Loland; Rajeev I Desai; Mu-Fa Zou; Jianjing Cao; Peter Grundt; Klaus Gerstbrein; Harald H Sitte; Amy Hauck Newman; Jonathan L Katz; Ulrik Gether
Journal:  Mol Pharmacol       Date:  2007-10-31       Impact factor: 4.436

8.  Mechanism of chloride interaction with neurotransmitter:sodium symporters.

Authors:  Elia Zomot; Annie Bendahan; Matthias Quick; Yongfang Zhao; Jonathan A Javitch; Baruch I Kanner
Journal:  Nature       Date:  2007-08-19       Impact factor: 49.962

9.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.

Authors:  Satinder K Singh; Atsuko Yamashita; Eric Gouaux
Journal:  Nature       Date:  2007-08-08       Impact factor: 49.962

10.  LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.

Authors:  Zheng Zhou; Juan Zhen; Nathan K Karpowich; Regina M Goetz; Christopher J Law; Maarten E A Reith; Da-Neng Wang
Journal:  Science       Date:  2007-08-09       Impact factor: 47.728

View more
  30 in total

Review 1.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113.

Authors:  Erik R Hill; Xiaoqin Huang; Chang-Guo Zhan; F Ivy Carroll; Howard H Gu
Journal:  Neuropharmacology       Date:  2011-03-21       Impact factor: 5.250

3.  R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Authors:  Claus J Loland; Maddalena Mereu; Oluyomi M Okunola; Jianjing Cao; Thomas E Prisinzano; Sonia Mazier; Theresa Kopajtic; Lei Shi; Jonathan L Katz; Gianluigi Tanda; Amy Hauck Newman
Journal:  Biol Psychiatry       Date:  2012-04-25       Impact factor: 13.382

Review 4.  How LeuT shapes our understanding of the mechanisms of sodium-coupled neurotransmitter transporters.

Authors:  Aravind Penmatsa; Eric Gouaux
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

5.  Exploring Substrate Binding in the Extracellular Vestibule of MhsT by Atomistic Simulations and Markov Models.

Authors:  Ara M Abramyan; Matthias Quick; Catherine Xue; Jonathan A Javitch; Lei Shi
Journal:  J Chem Inf Model       Date:  2018-06-11       Impact factor: 4.956

6.  Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays.

Authors:  Hideaki Yano; Alessandro Bonifazi; Min Xu; Daryl A Guthrie; Stephanie N Schneck; Ara M Abramyan; Andrew D Fant; W Conrad Hong; Amy H Newman; Lei Shi
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

7.  Neurotransmitter and psychostimulant recognition by the dopamine transporter.

Authors:  Kevin H Wang; Aravind Penmatsa; Eric Gouaux
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

Review 8.  Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.

Authors:  Sankar Manepalli; Christopher K Surratt; Jeffry D Madura; Tammy L Nolan
Journal:  AAPS J       Date:  2012-08-24       Impact factor: 4.009

9.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

10.  Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Authors:  David J Lapinsky; Nageswari Yarravarapu; Tammy L Nolan; Christopher K Surratt; John R Lever; Michael Tomlinson; Roxanne A Vaughan; Howard M Deutsch
Journal:  ACS Med Chem Lett       Date:  2012-03-11       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.